MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

FDA Places Partial Clinical Hold on AML and MDS Trial

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on a phase I/II trial of OXi4503, a vascular disrupting agent...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...

Positive Results With Ivosidenib in Patients With High-Risk, Previously Treated AML

Treatment with ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, led to durable remissions among people with relapsed or refractory, IDH1-mutated acute myeloid leukemia...

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...

Beyond Ruxolitinib: Exploring the JAK Inhibitors Landscape

In 2011, the U.S. Food and Drug Administration (FDA) approved ruxolitinib as the first therapy to treat myelofibrosis (MF), one of the group of...

Long-Term Follow-up Comparing Conditioning Regimens for Patients With AML Undergoing HCT

Nearly 10 years after allogeneic hematopoietic cell transplantation (HCT), patients with acute myeloid leukemia (AML) who received either reduced-intensity conditioning or myeloablative conditioning had...

Myeloid Malignancies: The Next Frontier for Immunotherapy

Building on the success of chimeric antigen receptor (CAR) T-cell therapies in lymphocytic leukemia and certain lymphomas – and the advances seen with checkpoint...

Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions

In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...

Final Results From PERSIST-2: Pacritinib Superior to Best Available Therapy in Patients With Myelofibrosis...

The development of the JAK2/FLT3 inhibitor pacritinib has been marked by ups and downs. In the phase III PERSIST-1 and PERSIST-2 trials, the drug...

The Genetic Signatures of AML Vary Between Younger and Older Patients

Acute myeloid leukemia (AML) is a collection of molecularly diverse diseases with similar phenotypes, and the distribution of these diseases differs between children and...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.